Grunnleggende statistikk
| CIK | 1164888 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to K2X Technology & Life Science, Inc.
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 15-12G 1 form15-12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 5-80125 Kyto Technology and Life Science, Inc. (Exa |
|
| May 9, 2022 |
SC TO-I/A 1 formsctoia.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 501572 |
|
| May 9, 2022 |
S-8 POS 1 forms-8pos.htm As filed with the Securities and Exchange Commission on May 9, 2022 Registration No. 333-120582 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENTS UNDER THE SECURITIES ACT OF 1933 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 65-1 |
|
| May 9, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| May 9, 2022 |
*Kyto Technology & Life Science Inc. Announces the Termination of Tender Offer* Exhibit 99.1 Item 9.01. Financial Statements and Exhibits. Exhibit 99.1 Press release dated May 5, 2022 *Kyto Technology & Life Science Inc. Announces the Termination of Tender Offer* May 5, 2022 Los Altos Hills, California?Kyto Technology & Life Science, Inc. (OTCQB: KBPH) (the ?Company? or ?Kyto?), today announced that it has terminated its previously announced tender offer to allow amendment of |
|
| May 5, 2022 |
EX-1.04 41 exa-1d.htm |
|
| May 5, 2022 |
Exhibit (a)(1)(A) |
|
| May 5, 2022 | ||
| May 5, 2022 |
SC TO-I/A 1 formsctoia.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Warrants to Purchase Common Stock (Title of Class of Securities) 50157 |
|
| May 5, 2022 |
EX-1.03 30 exa-1c.htm |
|
| May 4, 2022 |
SC TO-I/A 1 formsctoia.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Warrants to Purchase Common Stock (Title of Class of Securities) 50157 |
|
| April 22, 2022 |
Exhibit (a)(1)(D) NOTICE OF WITHDRAWAL THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 5:00 P. |
|
| April 22, 2022 |
April 22, 2022 Division of Corporate Finance Office of Life Sciences Securities and Exchange Commission Washington, D. |
|
| April 22, 2022 |
EX-1.02 3 exa-1b.htm Exhibit (A)(1)(B) NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE TRANSACTION CONTEMPLATED HEREIN; PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION; OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. OFFER TO AMEND AND EX |
|
| April 22, 2022 |
SC TO-I/A 1 formsctoa.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 501572 200 (CUSIP Number o |
|
| April 22, 2022 |
Exhibit (a)(1)(C) INSTRUCTIONS FOR ELECTION TO PARTICIPATE Your right to participate in the Offer to Amend and Exercise (the ?Exercise Offer?) of Kyto Technology and Life Science, Inc. |
|
| April 22, 2022 |
EX-1.01 2 exa-1a.htm Exhibit (a)(1)(A) [Company Letterhead] Kyto Technology and Life Science, Inc. 13050 La Paloma Road Los Altos Hills, CA 94022 Telephone: 650-204-7896 April 1, 2022 To the Holders of the Original Warrants: Kyto Technology and Life Science, Inc. (“we” or the “Company”) is offering you, as a holder of certain warrants to purchase common stock of the Company (the “Original Warrants |
|
| April 1, 2022 |
EX-1.01 2 exa-1a.htm Exhibit (a)(1)(A) [Company Letterhead] Kyto Technology and Life Science, Inc. 13050 La Paloma Road Los Altos Hills, CA 94022 Telephone: 650-204-7896 April 1, 2022 To the Holders of the Original Warrants, Kyto Technology and Life Science, Inc. (“we” or the “Company”) is offering you, as a holder of certain warrants to purchase common stock of the Company (the “Original Warrants |
|
| April 1, 2022 |
Exhibit 107 CALCULATION OF FILING FEE: Transaction valuation(1) Amount of filing fee(1)(2) $9,580,002 $888. |
|
| April 1, 2022 |
SC TO-I 1 formscto.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 501572 200 (CUSIP Number of C |
|
| April 1, 2022 |
Exhibit (A)(1)(B) NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE TRANSACTION CONTEMPLATED HEREIN; PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION; OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS DOCUMENT. |
|
| April 1, 2022 |
EX-1.04 5 exa-1d.htm Exhibit (a)(1)(D) NOTICE OF WITHDRAWAL THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 5:00 P.M. (PDT), ON MAY 2, 2022, UNLESS EXTENDED To: Kyto Technology and Life Science, Inc. 13050 La Paloma Road Los Altos Hills, CA 94022 Telephone: 650-204-7896 Email: [email protected] INSTRUCTIONS TO NOTICE OF WITHDRAWAL If you have previously elected to accept the Offer to Amend and Exercise |
|
| April 1, 2022 |
EX-1.03 4 exa-1c.htm Exhibit (a)(1)(C) INSTRUCTIONS FOR ELECTION TO PARTICIPATE Your right to participate in the Offer to Amend and Exercise (the “Exercise Offer”) of Kyto Technology and Life Science, Inc. (the “Company”) will automatically expire if you do not properly elect to participate on or before the Expiration Date of May 2, 2022, as may be extended by the Company in its sole discretion. B |
|
| March 23, 2022 |
Division of Corporate Finance Office of Life Sciences Securities and Exchange Commission Washington, D. |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact name |
|
| February 15, 2022 |
NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR ☐ Form N-CEN For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Rep |
|
| February 9, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2022 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact nam |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR ☐ Form N-CEN For Period Ended: September 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Trans |
|
| November 10, 2021 |
Kyto Technology and Life Science, Inc. 2021 Stock and Incentive Plan EX-4.1 2 ex4-1.htm Exhibit 4.1 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. 2021 STOCK AND INCENTIVE PLAN Section 1. Purpose The purpose of the Plan is to promote the interests of the Company and its stockholders by aiding the Company in attracting and retaining employees, officers, consultants, advisors and Directors capable of assuring the future success of the Company, to offer such persons incentive |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 5, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| October 12, 2021 |
Certificate of Designation of Class B3 Convertible Preferred Stock. Exhibit 3.1 |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO TECHNOLOGY AND LIFE SCIENCE, IN |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact name of |
|
| September 8, 2021 |
Unregistered Sales of Equity Securities 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-50390 65-108-6538 (State or Other Jurisdiction o |
|
| August 18, 2021 |
Unregistered Sales of Equity Securities 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-50390 65-108-6538 (State or Other Jurisdiction o |
|
| August 17, 2021 |
Exhibit 10.1 |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR [ ] Form N-CEN For Period Ended: June 30, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report o |
|
| August 17, 2021 |
Letter from OUM & Co. LLP, to the Securities and Exchange Commission, dated August 16, 2021. EX-16.1 3 ex16-1.htm Exhibit 16.1 |
|
| August 12, 2021 |
10-K/A 1 f10ka03312110kz.htm FORM 10-K/A AMENDED QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO TECHNOLOGY AND LIFE SCI |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact name of reg |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (check one): [X]Form 10-K[ ] Form 20-F[ ] Form 11-K[ ] Form 10-Q [ ] Form 10-D[ ] Form N-SAR[ ] Form N-CSR[ ] Form N-CEN For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (check one): [X]Form 10-K[ ] Form 20-F[ ] Form 11-K[ ] Form 10-Q [ ] Form 10-D[ ] Form N-SAR[ ] Form N-CSR[ ] Form N-CEN For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form |
|
| June 1, 2021 |
8-K 1 f8k0526218k.htm FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-50390 65-108-6538 (Stat |
|
| June 1, 2021 |
EXHIBIT 3.1 CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF DESIGNATION OF CLASS A2 CONVERTIBLE PREFERRED STOCK OF KYTO TECHNOLOGY AND LIFE SCIENCE, INC. Kyto Technology and Life Science, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify: 1.The name of the Corporation is Kyto Technology and Life Science, I |
|
| June 1, 2021 |
EX-16.1 3 f8k052621ex16z1.htm EXHIBIT 16.1 LETTER FROM RBSM LLP, TO THE SECURITIES AND EXCHANGE COMMISSION, DATED JUNE 1, 2021. Exhibit 16.1 June 1, 2021 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Kyto Technology & Life Sciences, Inc. (the “Company”). We reported on the consolidated financial statements of the Compan |
|
| April 14, 2021 |
EX-3.2 3 f8k040821ex3z2.htm EXHIBIT 3.2 CERTIFICATE OF DESIGNATION OF CLASS A2 CONVERTIBLE PREFERRED STOCK. |
|
| April 14, 2021 | ||
| April 14, 2021 |
8-K 1 f8k0408218k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 8, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-50390 65-108-6538 (Stat |
|
| April 14, 2021 |
EX-3.4 5 f8k040821ex3z4.htm EXHIBIT 3.4 CERTIFICATE OF DESIGNATION OF CLASS B2 CONVERTIBLE PREFERRED STOCK. |
|
| April 14, 2021 |
EX-3.1 2 f8k040821ex3z1.htm EXHIBIT 3.1 CERTIFICATE OF DESIGNATION OF CLASS A1 CONVERTIBLE PREFERRED STOCK. |
|
| April 12, 2021 |
8-K 1 f8k0405218k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-50390 65-108-6538 (Stat |
|
| April 12, 2021 | ||
| February 17, 2021 |
EX-3.2 3 f8k021021ex3z2.htm EXHIBIT 3.2 CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF DESIGNATION OF CLASS B CONVERTIBLE PREFERRED STOCK OF KYTO TECHNOLOGY AND LIFE SCIENCE, INC. Kyto Technology and Life Science, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: 1.The name of the Corporation is Kyto Tec |
|
| February 17, 2021 |
EX-3.1 2 f8k021021ex3z1.htm EXHIBIT 3.1 CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF DESIGNATION OF CLASS A CONVERTIBLE PREFERRED STOCK OF KYTO TECHNOLOGY AND LIFE SCIENCE, INC., FILED FEBRUARY 10, 2021 CERTIFICATE OF CORRECTION OF THE CERTIFICATE OF DESIGNATION OF CLASS A CONVERTIBLE PREFERRED STOCK OF KYTO TECHNOLOGY AND LIFE SCIENCE, INC. Kyto Technology and Life Science, Inc., a corporation |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| February 16, 2021 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT 10-Q 1 f10q12312010q.htm FORM 10-Q QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro |
|
| February 4, 2021 |
EX-10.1 2 f8k020121ex10z1.htm EXHIBIT 10.1 EMPLOYMENT AGREEMENT BETWEEN KYTO TECHNOLOGY AND LIFE SCIENCE, INC. AND PAUL RUSSO, DATED FEBRUARY 1, 2021 |
|
| February 4, 2021 |
Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| January 21, 2021 |
EX-10.1 2 f8k012121ex10z1.htm EXHIBIT 10.1 EMPLOYMENT AGREEMENT BETWEEN KYTO TECHNOLOGY AND LIFE SCIENCE, INC. AND PAUL RUSSO, DATED JANUARY 17, 2020 |
|
| January 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| January 14, 2021 |
KYTO TECHNOLOGY & LIFE SCIENCE, INC. 2020 NON-QUALIFIED STOCK OPTION PLAN EX-4.1 2 f8k010821ex4z1.htm EXHIBIT 4.1 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. 2020 NON-QUALIFIED STOCK OPTION PLAN KYTO TECHNOLOGY & LIFE SCIENCE, INC. 2020 NON-QUALIFIED STOCK OPTION PLAN Section 1. Purpose The purpose of the Plan is to promote the interests of the Company and its stockholders by aiding the Company in attracting and retaining consultants, independent contractors, advisors and No |
|
| January 14, 2021 |
8-K 1 f8k0108218k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2021 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-50390 65-108-6538 (St |
|
| November 20, 2020 |
Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO TECHNOLOGY AND LIFE SCIE |
|
| November 10, 2020 |
SC TO-I/A 1 toia2110620sctoiz.htm SCHEDULE TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class |
|
| November 9, 2020 |
SEC Response Letter November 9, 2020 Division of Corporation Finance Office of Mergers and Acquisitions Securities and Exchange Commission 100 F Street, N. |
|
| November 3, 2020 |
Schedule TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 501572 200 (CUSIP Nu |
|
| November 3, 2020 |
Exhibit 99a2A Public Announcement KYTO TECHNOLOGY AND LIFE SCIENCE, INC. PUBLIC ANNOUNCEMENT EXTENSION OF TENDER OFFER UNTIL 5:00 P.M., PACIFIC TIME, ON NOVEMBER 9, 2020 November [●], 2020 This Public Announcement serves to inform all interested parties that Kyto Technology and Life Science, Inc. (the “Company”) has elected to extend the expiration date for its offer to amend and exercise the Comp |
|
| October 1, 2020 |
Exhibit 99(a)(1)(A) Letter to Holders of Original Warrants Exhibit (a)(1)(A) [Company Letterhead] Kyto Technology and Life Science, Inc. |
|
| October 1, 2020 |
EX-99.A1C 4 toi093020ex99za1c.htm EXHIBIT 99(A)(1)(C) FORM OF ELECTION TO PARTICIPATE Exhibit (a)(1)(C) INSTRUCTIONS FOR ELECTION TO PARTICIPATE Your right to participate in the Offer to Amend and Exercise (the “Exercise Offer”) of Kyto Technology and Life Science, Inc. (the “Company”) will automatically expire if you do not properly elect to participate on or before the Expiration Date of October |
|
| October 1, 2020 |
Exhibit 99(a)(1)(D) Form of Notice of Withdrawal Exhibit (a)(1)(D) NOTICE OF WITHDRAWAL THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 5:00 P. |
|
| October 1, 2020 |
SC TO-I 1 toi093020sctoi.htm SCHEDULE TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 501572 20 |
|
| October 1, 2020 |
EX-99.A1B 3 toi093020ex99za1b.htm EXHIBIT 99(A)(1)(B) OFFER TO AMEND AND EXERCISE WARRANTS TO PURCHASE COMMON STOCK Exhibit (A)(1)(B) NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE TRANSACTION CONTEMPLATED HEREIN; PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION; OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN |
|
| August 6, 2020 |
Quarterly Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2020 |
Quarterly Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2020 |
Quarterly Report - FORM 10Q QUARTERLY REPORT Form 10Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 14, 2020 |
EX-3.1 2 f8k071320ex3z1.htm EXHIBIT 3.1 CLASS B CERTIFICATE OF DESIGNATION |
|
| July 14, 2020 |
8-K 1 f8k0713208k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2020 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-50390 65-108-6538 (State |
|
| July 2, 2020 |
Annual Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 30, 2020 |
Auditors preferability letter re adoption of ASC 946*** EX-18.1 3 f10k033120ex18z1.htm EXHIBIT 18.1 AUDITORS PREFERABILITY LETTER READOPTION OF ASC 946 Exhibit 18.1 June 30, 2020 Board of Directors and Stockholders of Kyto Technology and Life Science, Inc. 13050 La Paloma Road Los Altos Hills, CA 94022 Dear Directors: We are providing this letter to you for inclusion as an exhibit to your Form 10-K filing pursuant to Item 601 of Regulation S-K. We have |
|
| June 30, 2020 |
- FORM NT 10-K NOTICE OF LATE FILING Form NT 10-K Notice of Late Filing OMB APPROVAL UNITED STATES OMB Number: 3235-0058 SECURITIES AND EXCHANGE COMMISSION Expires: February 28, 2022 Washington, D. |
|
| June 30, 2020 |
Exhibit 3(i)(c) Amended Articles of Incorporation Exhibit 3(i)(c) |
|
| June 30, 2020 |
Annual Report - FORM 10-K ANNUAL REPORT Form 10-K Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 3, 2020 |
KBPH / Kyto Biopharma, Inc. 10-Q - Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 5, 2019 |
KYTO TECHNOLOGY AND LIFE SCIENCE, INC. 2019 STOCK AND INCENTIVE PLAN EX-4.1 2 f10q093019ex4z1.htm EXHIBIT 4.1 2019 STOCK INCENTIVE PLAN Exhibit 4.1 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. 2019 STOCK AND INCENTIVE PLAN Section 1. Purpose The purpose of the Plan is to promote the interests of the Company and its shareholders by aiding the Company in attracting and retaining employees, officers, consultants, advisors and non-employee Directors capable of assuring the f |
|
| November 5, 2019 |
KBPH / Kyto Biopharma, Inc. 10-Q - Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 2, 2019 |
KBPH / Kyto Biopharma, Inc. 10-Q/A - Quarterly Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 31, 2019 |
KBPH / Kyto Biopharma, Inc. 10-Q - Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 19, 2019 |
Delaware incorporation and revised articles of incorporation ** Exhibit 3.2 Delaware Certificate of Incorporation CERTIFICATE OF INCORPORATION OF KYTO TECHNOLOGY AND LIFE SCIENCE, INC. I, the undersigned, for the purpose of creating and organizing a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “DGCL”), certify as follows: 1. The name of the corporation is Kyto Technology and Li |
|
| July 19, 2019 |
Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2019 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| July 19, 2019 |
Bylaws of Kyto Technology and Life Science Inc. ** Exhibit 3.3 Delaware Bylaws BYLAWS OF KYTO TECHNOLOGY & LIFE SCIENCE, INC. Adopted July 19, 2019 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 3 1.1 Place of Meetings 3 1.2 Annual Meeting 3 1.3 Special Meeting 3 1.4 Notice of Stockholders’ Meetings 3 1.5 Quorum 3 1.6 Adjourned Meeting Notice 4 1.7 Conduct of Business 4 1.8 Voting 4 1.9 Stockholder Action by Written Consent Without a |
|
| July 19, 2019 |
Certificate of Conversion Florida Profit Corporation Delaware Profit Corporation Exhibit 3.5 Florida Certificate of Conversion Certificate of Conversion For Florida Profit Corporation Into Delaware Profit Corporation This Certificate of Conversion is submitted to convert the following Florida Profit Corporation into a Delaware Profit Corporation in accordance with s. 607.1113, Florida Statutes. 1.The name of the Florida Profit Corporation converting into the Delaware Profit Co |
|
| July 19, 2019 |
Exhibit 2.1 Plan of Conversion PLAN OF CONVERSION FOR CONVERTING KYTO TECHNOLOGY AND LIFE SCIENCE, INC., a Florida corporation TO KYTO TECHNOLOGY AND LIFE SCIENCE, INC., a Delaware corporation This Plan of Conversion (together with all of the exhibits attached hereto, the “Plan”), dated July 8, 2019, is hereby adopted by Kyto Technology and Life Science, Inc., a Florida corporation (the “Corporati |
|
| July 19, 2019 |
Exhibit 3.4 Class A Certificate of Designations CERTIFICATE OF DESIGNATION OF CLASS A CONVERTIBLE PREFERRED STOCK OF KYTO TECHNOLOGY AND LIFE SCIENCE, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Kyto Technology and Life Science, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in acc |
|
| July 19, 2019 |
Exhibit 3.1 Delaware Certificate of Conversion STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW 1.The jurisdiction where the Non-Delaware Corporation first formed is Florida. 2.The jurisdiction immediately prior to filing this Certificate of Conversion is Florida. 3.The date the Non |
|
| July 8, 2019 |
Submission of Matters to a Vote of Security Holders Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2019 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. |
|
| June 17, 2019 |
KBPH / Kyto Biopharma, Inc. DEF 14A - - DEFINITIVE 14A PROXY STATEMENT DEF 14A 1 def14a061719def14a.htm DEFINITIVE 14A PROXY STATEMENT SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| June 12, 2019 |
KBPH / Kyto Biopharma, Inc. PRER14A - - REVISED PRELIMINARY 14A PROXY STATEMENT Revised Preliminary 14A Proxy Statement SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. |
|
| June 12, 2019 |
KBPH / Kyto Biopharma, Inc. CORRESP - - SEC Response Letter June 12, 2019 Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F Street, N. |
|
| June 4, 2019 |
KBPH / Kyto Biopharma, Inc. PRER14A - - REVISED PRELIMINARY 14A PROXY STATEMENT Revised Preliminary 14A Proxy Statement SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. |
|
| June 4, 2019 |
KBPH / Kyto Biopharma, Inc. CORRESP - - SEC Response Letter June 4, 2019 Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F Street, N. |
|
| May 22, 2019 |
KBPH / Kyto Biopharma, Inc. PRE 14A - - PRELIMINARY 14A PROXY STATEMENT Preliminary 14A Proxy Statement SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material under §240. |
|
| May 16, 2019 |
KBPH / Kyto Biopharma, Inc. 10-K Annual Report FORM 10K ANNUAL REPORT Form 10K Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 12, 2019 |
KBPH / Kyto Biopharma, Inc. FORM 10Q QUARTERLY REPORT (Quarterly Report) Form 10Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 30, 2018 |
KBPH / Kyto Biopharma, Inc. FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 20, 2018 |
KBPH / Kyto Biopharma, Inc. FORM 10Q QUARTERLY REPORT (Quarterly Report) 10-Q 1 f10q06301810q.htm FORM 10Q QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to |
|
| August 20, 2018 |
EX-3.IC 2 f10q063018ex3zic.htm EXHIBIT 3(I)(C) CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION FILED APRIL 25, 2018 |
|
| August 20, 2018 |
Exhibit 10.7 Subscription Agreement for Private Placement April 2018 |
|
| August 15, 2018 |
KBPH / Kyto Biopharma, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| June 28, 2018 |
KBPH / Kyto Biopharma, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☑· ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2018 OR ☐· TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact name of registrant as specified in its charter) |
|
| May 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) April 25, 2018 Kyto BioPharma Inc. (Exact name of registrant as specified in its charter) Florida 65-108-6538 (State or other jurisdiction (I.R.S. Employer incorporation or organization) Identificatio |
|
| February 22, 2018 |
KBPHD / Kyto Biopharma, Inc. / BENARROCH GEORGES - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* KYTO BIOPHARMA INC. (Name of Issuer) COMMON STOCK $.0001 PAR VALUE (Title of Class of Securities) 501572200 (CUSIP Number) GEORGES BENARROCH, 78 HAZELTON AVE., TORONTO ON M5R 2E2 COMINDUS FINANCE CORP 134 DUKE DRIVE, LAKE WORTH FL 33460 1-866-484-5831 (Na |
|
| February 14, 2018 |
KBPH / Kyto Biopharma, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name o |
|
| November 14, 2017 |
KBPH / Kyto Biopharma, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name |
|
| August 14, 2017 |
KBPH / Kyto Biopharma, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of re |
|
| June 29, 2017 |
KBPH / Kyto Biopharma, Inc. ANNUAL REPORT (Annual Report) 10-K 1 kbph10k.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☑· ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2017 OR ☐· TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in |
|
| February 14, 2017 |
Kyto Biopharma QUARTERLY REPORT (Quarterly Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Ex |
|
| November 14, 2016 |
Kyto Biopharma QUARTERLY REPORT (Quarterly Report) Untitled Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, |
|
| August 15, 2016 |
Kyto Biopharma PRIMARY DOCUMENT (Quarterly Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact |
|
| August 15, 2016 |
Kyto Biopharma PRIMARY DOCUMENT (Quarterly Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact |
|
| June 29, 2016 |
Kyto Biopharma ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☑· ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2016 OR ☐· TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 |
|
| February 16, 2016 |
KBPH / Kyto Biopharma, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name o |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name |
|
| September 28, 2015 |
kbph8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) September 24, 2015 Kyto BioPharma Inc. (Exact name of registrant as specified in its charter) Florida 65-108-6538 (State or other jurisdiction (I.R.S. Employer incorporation or organization |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of re |
|
| June 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 (S |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name o |
|
| February 13, 2015 |
Schedule 13G Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Kyto Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 501572101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name |
|
| October 9, 2014 |
KBPH / Kyto Biopharma, Inc. / BENARROCH GEORGES - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* KYTO BIOPHARMA INC. (Name of Issuer) COMMON STOCK $.0001 PAR VALUE (Title of Class of Securities) 501572101 (CUSIP Number) GEORGES BENARROCH, 49 AVE FOCH PARIS FRANCE 75116 1-888-231-7511 COMINDUS FINANCE CORP 500 AUSTRALIAN AVE S # 600 WEST PALM BEACH FL 33401 1-866-4 |
|
| October 6, 2014 |
KBPH / Kyto Biopharma, Inc. / BRISTOL MYERS SQUIBB CO - SCHEDULE 13G Passive Investment SC 13G 1 d802666dsc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Kyto Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 501572101 (CUSIP Number) September 30, 2014 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of re |
|
| June 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 (S |
|
| February 14, 2014 |
Kyto Biopharma QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name o |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name |
|
| September 30, 2013 |
Entry into a Material Definitive Agreement 8-K 1 kbph8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) September 26, 2013 Kyto BioPharma Inc. (Exact name of registrant as specified in its charter) Florida 65-108-6538 (State or other jurisdiction (I.R.S. Employer incorpor |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of re |
|
| July 22, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) July 17, 2013 Kyto BioPharma Inc. (Exact name of registrant as specified in its charter) Florida 65-108-6538 (State or other jurisdiction (I.R.S. Employer incorporation or organization) Identification |
|
| July 22, 2013 |
Kyto BioPharma Inc. Announces Letter of Intent to Acquire Barbados Sea Island Cotton Inc. Exhibit 99.1 Kyto BioPharma Inc. Announces Letter of Intent to Acquire Barbados Sea Island Cotton Inc. Palm Beach Gardens FL– July 22, 2013 – Kyto BioPharma Inc. (“Kyto”) (OTCQB: KBPH) is pleased to announce that it has entered into a Letter of Intent to acquire all of the outstanding common shares of Barbados Sea Island Cotton Inc. (“BSC”) through the issuance of 10 million common shares of Kyto |
|
| June 28, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 (S |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2012 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name o |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of re |
|
| June 29, 2012 |
PLATFORM TECHNOLOGY, PATENT AND PATENT APPLICATION ASSIGNMENT AGREEMENT EX-2.1 2 kbphex21.htm Exhibit 2.1 PLATFORM TECHNOLOGY, PATENT AND PATENT APPLICATION ASSIGNMENT AGREEMENT THIS AGREEMENT made as of the 31st day of May, 2012 BETWEEN KYTO BIOPHARMA INC. a company incorporated pursuant to the laws of the State of Florida and having an office at 3801 PGA Boulevard, Suite 802, Palm Beach Gardens, Florida (hereinafter the “Vendor**”) OF THE FIRST PART - and – KYTO IP |
|
| June 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) June 29, 2012 Kyto BioPharma Inc. (Exact name of registrant as specified in its charter) Florida 65-108-6538 (State or other jurisdiction (I.R.S. Employer incorporation or organization) Identification |
|
| June 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 (S |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name o |
|
| December 12, 2011 |
Kyto BioPharma, Inc. Patent Family Summary Exhibit B Kyto BioPharma, Inc. Patent Family Summary 1. The 401 Patent Family – “Anti-Receptor Agents” In general terms, the 401 family is directed to anti-receptor and growth blocking agents which antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites on the B12/TcII complex. This results in the cellular depletion of vitamin B12, thus preventing or inhibiting cell divi |
|
| December 12, 2011 |
EXHIBIT A |
|
| December 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A No. 3 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-10 |
|
| December 12, 2011 |
EXHIBIT C |
|
| November 30, 2011 |
Kyto Biopharma Inc. c/o 114 Belmont Street Toronto ON M5R 1P8 telephone (416) 884-8807 telecopier (416)884-8807 [email protected] November 29, 2011 ‘CORESP’ United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Form 10-K/A for the Year Ended December 31, 2010 Filed November 14,2011 File No. 000-50390 Attention: Jeffrey Riedler Dear Mr. Riedler; The Company i |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name |
|
| November 14, 2011 |
Kyto Biopharma Inc. c/o 114 Belmont Street Toronto ON M5R 1P8 telephone (416) 884-8807 telecopier (416)884-8807 [email protected] November 9, 2011 ‘CORESP’ United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Kyto Biopharma, Inc. Form 10-K for the Fiscal Year Ended March 31, 2011 Filed June 29, 2011 Form 10-K/A for the Year Ended December 31, 2010 Filed Oct |
|
| November 8, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A No. 2 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-10 |
|
| November 8, 2011 |
Kyto BioPharma, Inc. Patent Family Summary Exhibit 99.2 Kyto BioPharma, Inc. Patent Family Summary 1. The 401 Patent Family – “Anti-Receptor Agents” In general terms, the 401 family is directed to anti-receptor and growth blocking agents which antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites on the B12/TcII complex. This results in the cellular depletion of vitamin B12, thus preventing or inhibiting cell d |
|
| November 8, 2011 |
EXHIBIT 99.1 |
|
| November 8, 2011 |
EXHIBIT 99.3 |
|
| October 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 |
|
| October 13, 2011 |
Kyto BioPharma, Inc. Patent Family Summary Exhibit 99.2 Kyto BioPharma, Inc. Patent Family Summary 1. The 401 Patent Family – “Anti-Receptor Agents” In general terms, the 401 family is directed to anti-receptor and growth blocking agents which antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites on the B12/TcII complex. This results in the cellular depletion of vitamin B12, thus preventing or inhibiting cell d |
|
| October 13, 2011 |
EXHIBIT 99.3 |
|
| October 13, 2011 |
EXHIBIT 99.1 |
|
| September 21, 2011 |
Kyto Biopharma Inc. c/o 114 Belmont Street Toronto ON M5R 1P8 telephone (416) 884-8807 telecopier (416)884-8807 [email protected] September 20, 2011 ‘CORESP’ United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Kyto BioPharma, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended March 31, 2011 Filed June 29, 2011 File No. 000-50390 Attention: Melissa N. |
|
| August 26, 2011 |
Kyto Biopharma Inc. c/o 114 Belmont Street Toronto ON M5R 1P8 telephone (416) 884-8807 telecopier (416)884-8807 [email protected] August 24, 2011 ‘CORESP’ United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Kyto BioPharma, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended March 31, 2011 Filed June 29, 2011 File No. 000-50390 Attention: Melissa N. Ro |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of re |
|
| June 29, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 (S |
|
| May 9, 2011 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2011 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 000-50390 65-1086538 (Commission File Num |
|
| May 9, 2011 |
JEWETT, SCHWARTZ ,WOLFE & ASSOCIATES HOLLYWOOD, FL May 9, 2011 EXHIBIT 16.1 JEWETT, SCHWARTZ ,WOLFE & ASSOCIATES HOLLYWOOD, FL May 9, 2011 Securities and Exchange Commission 100 F Street, N.W. Washington, DC 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Kyto Biopharma, Inc., (the ?Company?) Form 8-K dated May 9, 2011, and are in agreement with the statements relating only to Jewett, Schwartz, Wolfe & Associates contained therein. We have no basis to |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2010 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name o |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name |
|
| August 30, 2010 |
SCHNEIDER WEINBERGER & BEILLY LLP 2200 Corporate Boulevard, N.W. Suite 210 Boca Raton, Florida 33431 telephone (561) 362-9595 telecopier (561) 362-9612 [email protected] August 30, 2010 ‘CORESP’ United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Kyto BioPharma, Inc. (the “Company”) Item 4.02 Form 8-K Filed August 23, 2010 File No. 000-50390 Attention: Christ |
|
| August 26, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 |
|
| August 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of re |
|
| August 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) August 23, 2010 Kyto BioPharma Inc. (Exact name of registrant as specified in its charter) Florida 65-108-6538 (State or other jurisdiction (I.R.S. Employer incorporation or organization) Identificati |
|
| August 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K þ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2010 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 1 |
|
| June 30, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTO BIOPHARMA INC. (Exact name of registrant as specified in its charter) FLORIDA 65-1086538 (S |
|
| May 7, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 07, 2010 Kyto Biopharma Inc. |
|
| May 7, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 07, 2010 Kyto Biopharma Inc. |
|
| April 7, 2010 |
United States Securities & Exchange Commission EDGAR Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ——————— .. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? .. ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2009 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact nam |
|
| November 13, 2009 |
United States Securities & Exchange Commission EDGAR Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— . þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to KYTO BIOPHARMA, INC. (Exact name of |
|
| August 14, 2009 |
United States Securities and Exchange Commission Edgar Filing EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Kyto Biopharma, Inc. and Subsidiary (the “Company”) on Form 10-Q for the three months ended June 30, 2009, as filed with the Securities and Exchange Commission on t |
|
| July 6, 2009 |
KYTO BIOPHARMA INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) June 29, 2009 Kyto BioPharma Inc. (Exact name of registrant as specified in its charter) Florida 65-108-6538 (State or other jurisdiction (I.R.S. Employer incorporation or organiza |
|
| June 29, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-K ??????? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: or For the transition period from: to COMMISSION FILE NO. 000-28107 ??????? KYTO BIOPHARMA INC. ( |
|
| February 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q KYTO BIOPHARMA INC (Form: 10QSB, Received: 02/24/2006 14:32:59) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 6, 2008 |
KYTO BIOPHARMA INC (Form: 10QSB, Received: 02/24/2006 14:32:59) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 12, 2008 |
United States Securities and Exchange Commission EDGAR Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 27, 2006 |
United States Securities & Exchange Commission EDGAR Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 17, 2006 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 28, 2005 |
EXHIBIT 16.1 July 26, 2005 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Kyto Biopharma, Inc. File Reference No. 000-50390 We were previously the independent registered public accounting firm for Kyto Biopharma, Inc. and under the date of June 6, 2005, we reported on the consolidated financial statements of Kyto Biopharma, Inc. and Subs |
|
| July 28, 2005 |
BP - x1-54504 - Kyto Biopharma, Inc. - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2005 KYTO BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) FLORIDA 65-1086538 (State or other jurisdiction of |
|
| September 12, 2003 |
Articles of Amendment changing name to Kyto Technology and Life Science Inc * EXHIBIT 3(i)(b) ARTICLES OF AMENDMENT FOR B. TWELVE, INC. Pursuant to Florida Statutes Section 607.1006, the Articles of Incorporation of the above-named corporation are hereby amended as follows: 1. Article 4, Section 4.01 shall be restated in its entirety to state: 4.01 The aggregate number of shares which the corporation shall have the authority to issue is 1,000,000 preferred shares adn 25,000 |
|
| August 22, 2002 |
EX-10.1 3 ex10-1.txt SHAREHOLDERS AGREEMENT AMENDED AND RESTATED UNANIMOUS SHAREHOLDERS' AGREEMENT Amended and restated unanimous shareholders' agreement dated January 15, 2001 among B. TWELVE, INC. (herein "B 12" or the "Corporation"), DR. URI SAGMAN ("Sagman"), CREDIFINANCE CAPITAL CORP. ("Credifmance"), NEW RESEARCHES CORPORATION ("NRC"), LIFMAC, S.A. ("Lifmac"), GEORGES BENARROCH ("Benarroch") |
|
| July 31, 2002 |
EX-10.6 7 consultingagrmt-berger.txt BERGER CONSULTING AGREEMENT Exhibit 10.6 CONSULTING AGREEMENT BETWEEN: B TWELVE LIMITED (hereinafter referred to as the "Company") -and- JEAN-LUC BERGER, Ph.D. (hereinafter referred to as the "Executive") WHEREAS the Company is a wholly owned subsidiary of B. Twelve, Inc., a corporation existing under the laws of the State of Florida; and WHEREAS the Executive |
